[ Price : $8.95]
A Stanford Law School Center for the Law and Biosciences fellow says policymakers should consider the growth in breakthrough medic...[ Price : $8.95]
FDA grants Bayer a priority review for its NDA for asundexian, an investigational oral Factor XIa inhibitor designed to reduce the...[ Price : $8.95]
The U.S. Supreme Court declines to hear a series of pharmaceutical industry challenges to the governments Medicare drug price nego...[ Price : $8.95]
FDA faces renewed scrutiny of an internal FDA analysis of pediatric deaths reported after Covid-19 vaccination, following the rele...[ Price : $8.95]
FDA grants Bayer a priority review for its supplemental NDA for Hyrnuo (sevabertinib) as a first-line treatment for patients with ...[ Price : $8.95]
In an opern letter to president Trump, rare disease advocates urge him to push FDA to accelerate approvals for treatments targetin...[ Price : $8.95]
Regeneron Pharmaceuticals says its Phase 3 trial evaluating the experimental immunotherapy combination of fianlimab and cemiplimab...[ Price : $8.95]
Merck reports that its Phase 3 TroFuse-005 trial evaluating the investigational antibody-drug conjugate sacituzumab tirumotecan me...